Dai Shiyi,Peng Suhua,Chen Siyuan,et al.Recent advances in researches and treatments of kaposiform hemangioendothelioma[J].Journal of Clinical Pediatric Surgery,,19():544-547,553.[doi:10.3969/j.issn.1671-6353.2020.06.016]
Click Copy

Recent advances in researches and treatments of kaposiform hemangioendothelioma

Journal of Clinical Pediatric Surgery[ISSN:1671-6353/CN:43-1380/R] volume: 第19卷 Number: 2020 06 Page: 544-547,553 Column: 综述 Date of publication: 2020-06-15
Author(s):
Dai Shiyi1;  Peng Suhua1;  Chen Siyuan2;  Ji Yi1
1. Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China;
2. Pediatric Intensive Care Unit, West China Hospital, Sichuan University, Chengdu, 610041, China
Keywords:
Kaposiform Hemangioendothelioma; Therapy
CLC:
R543;R732.2
DOI:
10.3969/j.issn.1671-6353.2020.06.016
Abstract:
As a rare,endotheliogenic and locally aggressive vascular neoplasm appearing predominantly in infants and toddlers,kaposiform hemangioendothelioma (KHE) is characterized by diffuse and invasive vascular and lymphatic proliferation.It may be associated with thrombocytopenia,hypofibrinemia and coagulation factor consumption,which is also known as Kasabach-Merritt phenomenon (KMP).KMP can cause serious complications and even death.With the continuous progress of pathogenesis,clinical diagnosis and treatments of surgery,embolization and using vincristine and sirolimus,most children have a decent prognosis.However,decreased range of motion and chronic pain are likely to be underappreciated in clinical practice.In this review,recent advances in researches and treatments of KHE were summarized.With a review of the relevant literature,the clinical characteristics,major complications and risk factors of KHE were extensively discussed for its optimal clinical managements.

References:

1 Schmid I,Klenk AK,Sparber-Sauer MA,et al.Kaposiform hemangioendothelioma in children:a benign vascular tumor with multiple treatment options[J].World J Pediatr,2018,14(4):322-329.DOI:10.1007/s12519-018-0171-5.
2 Ji Y,Yang K,Peng S,et al.Kaposiform haemangioendothelioma:clinical features,complications and risk factors for Kasabach-Merritt phenomenon[J].Brit J Dermatol,2018,179(2):457-463.DOI:10.1111/bjd.16601.
3 Glaser K,Dickie P,Dickie BH.Proliferative cells from kaposiform lymphangiomatosis lesions resemble mesenchyme stem cell-like pericytes defective in vessel formation[J].J Pediatr Hematol Oncol,2018,40(8):e495-e504.DOI:10.1097/MPH.0000000000001284.
4 O’rafferty C,O’regan GM,Irvine AD,et al.Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon[J].Br J Haematol,2015,171(1):38-51.DOI:10.1111/bjh.13557.
5 Lim YH,Bacchiocchi A,Qiu J,et al.GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation[J].Am J Hum Genet,2016,99(2):443-450.DOI:10.1016/j.ajhg.2016.06.010.
6 Hall GW.Kasabach-Merritt syndrome:pathogenesis and management[J].Brit J Haematol,2001,112(4):851-862.DOI:10.1046/j.1365-2141.2001.02453.x.
7 Le Cras TD,Mobberley-Schuman PS,Broering M,et al.Angiopoietins as serum biomarkers for lymphatic anomalies[J].Angiogenesis,2017,20(1):163-173.DOI:10.1007/s10456-016-9537-2.
8 Croteau SE,Kozakewich HP,Perez-Atayde AR,et al.Kaposiform lymphangiomatosis:a distinct aggressive lymphatic anomaly[J].J Pediatr,2014,164(2):383-388.DOI:10.1016/j.jpeds.2013.10.013.
9 Ji Y,Chen SY,Yang KY,et al.Development of Kasabach-Merritt phenomenon following vaccination:more than a coincidence?[J].J Dermatol,2018,45(10):1203-1206.DOI:10.1111/1346-8138.14598.
10 Yue X,Zhao X,Dai YF,et al.Episode of Kasabach-Merritt phenomenon following Japanese encephalitis vaccination:case report[J].Vaccine,2017,35(48 Pt B):6594-6597.DOI:10.1016/j.vaccine.2017.08.011.
11 Choi JW,Na JI,Hong JS,et al.Intractable tufted angioma associated with Kasabach-Merritt syndrome[J].Ann Dermatol,2013,25(1):129-130.DOI:10.5021/ad.2013.25.1.129.
12 Liu QY,Jiang LL,Wu DT,et al.Clinicopathological features of Kaposiform hemangioendothelioma[J].Int J Clin Exp Pathol,2015,8(10):13711-13718.
13 Lisle JW,Bradeen HA,Kalof AN.Case report:kaposiform hemangioendothelioma in multiple spinal levels without skin changes[J].Clin Orthop Relat Res,2009,467(9):2464-2471.DOI:10.1007/s11999-009-0838-2.
14 Kim DW,Chung JH,Ahn SH,et al.Laryngeal kaposiform hemangioendothelioma:Case report and literature review[J].Auris Nasus Larynx,2010,37(2):258-262.DOI:10.1016/j.anl.2009.05.003.
15 Ji Y,Chen SY,Li LZ,et al.Kaposiform hemangioendothelioma without cutaneous involvement[J].J Cancer Res Clin Oncol,2018,144(12):2475-2484.DOI:10.1007/s00432-018-2759-5.
16 Ji Y,Chen SY,Xiang B,et al.Sirolimus for the treatment of progressive kaposiform hemangioendothelioma:A multicenter retrospective study[J].Int J Cancer,2017,141(4):848-855.DOI:10.1002/ijc.30775.
17 Mulliken JB,Young AE,Paletta FX.Vascular birthmarks[J].Plast Reconstr Surg,1990,85(3):471.DOI:10.1097/00006534-199003000-00027.
18 Gruman A,Liang MG,Mulliken JB,et al.Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon[J].J Am Acad Dermatol,2005,52(4):616-622.DOI:10.1016/j.jaad.2004.10.880.
19 Adams DM,Leonardo R,Brand?opeterman CM,et al.Vascular anomaly cases for the pediatric hematologist oncologists-An interdisciplinary review[J].Pediatr Blood Cancer,2017,65(3):e26716.DOI:10.1002/pbc.26716.
20 Oza VS,Mamlouk MD,Hess CP,et al.Role of sirolimus in advanced kaposiform hemangioendothelioma[J].Pediatr Dermatol,2016,33(2):e88-e92.DOI:10.1111/pde.12787.
21 Mahajan P,Margolin J,Iacobas I.Kasabach-Merritt phenomenon:classic presentation and management options[J].Clin Med Insights Blood Disord,2017,10:1179545X17699849.DOI:10.1177/1179545X17699849.
22 Triana PJ,Dore M,Vanesa CN,et al.Pancreatic kaposiform hemangioendothelioma not responding to sirolimus[J].Eur J Pediatr Surg,2017,5(1):e32-e35.DOI:10.1055/s-0037-1604358.
23 Liu XH,Li JY,Qu XH,et al.Clinical outcomes for systemic corticosteroids versus vincristine in treating kaposiform hemangioendothelioma and tufted angioma[J].Medicine (Baltimore),2016,95(20):e3431.DOI:10.1097/MD.0000000000003431.
24 Tlougan BE,Lee MT,Drolet BA,et al.Medical management of tumors associated with Kasabach-Merritt phenomenon:an expert survey[J].J Pediatr Hematol Oncol,2013,35(8):618-622.DOI:10.1097/MPH.0b013e318298ae9e.
25 Wu HW,Wang X,Zhang L,et al.Interferon-alpha therapy for refractory kaposiform hemangioendothelioma:a single-center experience[J].Sci Rep,2016,6(1):36261.DOI:10.1038/srep36261.
26 Liu XH,Li JY,Qu XH,et al.Treatment of kaposiform hemangioendothelioma and tufted angioma[J].Int J Cancer,2016,139(7):1658-1666.DOI:10.1002/ijc.30216.
27 Wang Z,Li K,Yao W,et al.Steroid-resistant kaposiform hemangioendothelioma:a retrospective study of 37 patients treated with vincristine and long-term follow-up[J].Pediatr Blood Cancer,2015,62(4):577-580.DOI:10.1002/pbc.25296.
28 Wiegand S,Wichmann G,Dietz A.Treatment of lymphatic malformations with the mTOR inhibitor sirolimus:a systematic review[J].Lymphat Res Biol,2018,16(4):330-339.DOI:10.1089/lrb.2017.0062.
29 Matsumoto H,Ozeki M,Hori T,et al.Successful everolimus treatment of kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon:clinical efficacy and adverse effects of mTOR inhibitor therapy[J].J Pediatr Hematol Oncol,2016,38(8):e322-e325.DOI:10.1097/MPH.0000000000000509.
30 Vierhuff W.Sirolimus in the treatment of vascular anomalies[J].Eur J Pediatr Surg,2017,27(1):86-90.DOI:10.1055/s-0036-1593383.
31 Russell TB,Rinker EK,Dillingham CS,et al.Pneumocystis JiroveciiPneumonia during sirolimus therapy for kaposiform hemangioendothelioma[J].Pediatrics,2018,141(Suppl 5):S421-S424.DOI:10.1542/peds.2017-1044.
32 Ying HR,Qiao C,Yang X,et al.A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas[J].Pediatrics,2018,141(5):S425-S429.DOI:10.1542/peds.2016-2919.

Memo

收稿日期:2019-04-15。
基金项目:国家自然科学基金资助项目（编号：81401606/81400862）；四川大学优秀青年学者基金资助项目（编号：2015SU04A15）；四川省科技厅重点研发项目（编号：2019YFS0322）
通讯作者:吉毅,Email:jijiyuanyuan@163.com

Last Update: 1900-01-01